Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APEX: Guselkumab in active psoriatic arthritis (Phase IIIb, randomized, double-blind, placebo-controlled)
CTR20223454Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of guselkumab in psoriatic arthritis (PsA), sponsored by Janssen Pharmaceutical. Started May 2023; status: active.
02
Drugs
guselkumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on CTR20223454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223454.